Policy
An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it didn’t follow the regulator’s recommendations in testing its mRNA flu vaccine.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
Wolters Kluwer, Health now equips astronauts at the National Aeronautics and Space Administration on board the International Space Station with the most current medical information and access to expert-authored recommendations.
labfolder is the first company amongst electronic laboratory notebook (ELN) and laboratory information management (LIMS) software vendors to announce its highly-ranked Net Promoter Score® (NPS®).
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
The FY19 Defense Appropriations Act provides $15 million to the Department of Defense Neurofibromatosis Research Program to support innovative, high-impact NF research.
Department of Defense Parkinson’s Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $16 million to the Department of Defense Parkinson’ Research Program to support research to understand, prevent, diagnose, and treat Parkinson’s disease.
The life sciences industry is incredibly important to the financial ecosystem of the Golden State. Last year the industry generated total annual revenue of $177.1 billion in the state.
Allergan, which has been a leader in the migraine space, hopes to have a new treatment available for patients using a new mechanism of action for acute treatment of migraine.
Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests